Race does not predict the development of metastases in men with nonmetastatic castration-resistant prostate cancer
详细信息 查看全文
- 作者：Colette A. Whitney ; Lauren E. Howard ; Christopher L. Amling ; William J. Aronson ; Matthew R. Cooperberg ; Christopher J. Kane ; Martha K. Terris and Stephen J. Freedland
- 刊名：Cancer
- 出版年：2016
- 出版时间：December 15, 2016
- 年：2016
- 卷：122
- 期：24
- 页码：3848-3855
- 全文大小：254K
- ISSN：1097-0142
文摘
Although race is associated with prostate cancer progression in early stage disease, once men have advanced disease, it is unclear whether race continues to predict a poor outcome. The authors hypothesized that, in an equal-access setting among patients with castration-resistant prostate cancer (CRPC) and no known metastases (M0/Mx), black men would receive imaging tests at similar rates as nonblack men (ie, there would be an equal opportunity to detect metastases) but would have a higher risk of metastatic disease.